Medline (MDLN) Stock Overview
Manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
MDLN Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Medline Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$35.84 |
| 52 Week High | US$50.88 |
| 52 Week Low | US$34.89 |
| Beta | 0 |
| 1 Month Change | -20.76% |
| 3 Month Change | -26.69% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -12.59% |
Recent News & Updates
Recent updates
Prime Vendor Contracts And Automation Investments Will Reshape Long Term Earnings Profile
Catalysts About Medline Medline is a vertically integrated manufacturer and distributor of medical supplies and supply chain services for health care providers across acute, non-acute and international markets. What are the underlying business or industry changes driving this perspective?Medline: A Lack Of Compelling Risk-Reward Makes Me Cautious
Summary Medline delivered strong Q4 momentum and 2025 sales growth, but recent margin pressure has left profits largely flat. Medline guides for 8-9% organic sales growth and modest adjusted EBITDA gains in 2026, yet margin compression remains a material concern. Selling shareholders, including Blackstone and Carlyle, recently offloaded a significant stake post lock-up, highlighting valuation sensitivity. At $44 per share, Medline trades at 31-33x forward earnings, a demanding multiple given segment margin discrepancies and leverage. Read the full article on Seeking AlphaShareholder Returns
| MDLN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.1% | -3.5% | 1.3% |
| 1Y | n/a | -21.9% | 27.7% |
Return vs Industry: Insufficient data to determine how MDLN performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how MDLN performed against the US Market.
Price Volatility
| MDLN volatility | |
|---|---|
| MDLN Average Weekly Movement | 5.5% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MDLN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine MDLN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | 45,000 | Jim Boyle | www.medline.com |
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics.
Medline Inc. Fundamentals Summary
| MDLN fundamental statistics | |
|---|---|
| Market cap | US$47.50b |
| Earnings (TTM) | US$966.00m |
| Revenue (TTM) | US$29.14b |
Is MDLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDLN income statement (TTM) | |
|---|---|
| Revenue | US$29.14b |
| Cost of Revenue | US$21.61b |
| Gross Profit | US$7.54b |
| Other Expenses | US$6.57b |
| Earnings | US$966.00m |
Last Reported Earnings
Mar 28, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.14 |
| Gross Margin | 25.86% |
| Net Profit Margin | 3.32% |
| Debt/Equity Ratio | 65.0% |
How did MDLN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/27 12:35 |
| End of Day Share Price | 2026/05/27 00:00 |
| Earnings | 2026/03/28 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medline Inc. is covered by 33 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Coldwell | Baird |
| Glen Santangelo | Barclays |
| Lee Hambright | Bernstein |